Should I Buy TRVI? TRVI 2026 Analysis

Should You Buy Trevi Therapeutics Inc (TRVI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

11.940

1 Day change

1.53%

52 Week Range

14.390

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Trevi Therapeutics Inc (TRVI) is not a strong buy for a beginner investor with a long-term focus at this time. While the stock shows some technical strength with bullish moving averages and a positive MACD, the overbought RSI and lack of significant positive catalysts, combined with weak financial performance, suggest caution. The absence of recent news, congress trading data, and Intellectia Proprietary Trading Signals further supports a hold recommendation.

Technical Analysis

The stock is in a bullish trend with SMA_5 > SMA_20 > SMA_200 and a positive MACD histogram of 0.274. However, the RSI_6 at 83.889 indicates the stock is overbought, suggesting a potential pullback. Key resistance is at 13.217, with support at 10.899.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Stifel raised the price target to $18 from $15 with a Buy rating, indicating analyst confidence in the stock's potential.

Neutral/Negative Catalysts

No significant hedge fund or insider trading activity. The stock is overbought based on RSI. Financial performance is weak, with a YoY decline in net income and EPS.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income dropped by -10.87% YoY to -$11.8M, and EPS fell by -38.46% YoY to -0.08. Gross margin remained at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Stifel maintains a Buy rating and raised the price target to $18 from $15, reflecting optimism for the stock's future performance.

9 Analyst Rating

Wall Street analysts forecast TRVI stock price to rise

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 11.760

Low

Averages

21.22

High

Current: 11.760

Low

Averages

21.22

High

Stifel

Buy

maintain

$15 -> $18

AI Analysis

2025-12-19

Reason

Stifel

Price Target

$15 -> $18

AI Analysis

2025-12-19

maintain

Buy

Reason

Stifel raised the firm's price target on Trevi Therapeutics to $18 from $15 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.

Oppenheimer

Leland Gershell

Outperform

maintain

$23 -> $24

2025-11-14

Reason

Oppenheimer

Leland Gershell

Price Target

$23 -> $24

2025-11-14

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on Trevi Therapeutics to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company provided updates across Haduvio's development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program - as well as advance into Phase 2b for refractory chronic cough - in the first half of 2026. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and Oppenheimer sees meaningful upside as Haduvio's momentum toward commercial builds for a growing group of poorly served chronic cough indications.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TRVI

Unlock Now

TRVI Should I Buy

TRVI Should I Buy

Should You Buy Trevi Therapeutics Inc (TRVI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch